Welcome to our dedicated page for Biohaven SEC filings (Ticker: BHVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biohaven Ltd.'s SEC filings document the formal disclosures of a British Virgin Islands clinical-stage biopharmaceutical company listed under BHVN. The filing record includes Form 8-K reports for operating results, Regulation FD presentations, clinical and regulatory pipeline updates, and material equity financing events involving common shares.
Proxy and annual-meeting filings cover director elections, auditor ratification, executive compensation votes and shareholder governance matters. Registration-related disclosures and prospectus supplements describe shelf registration mechanics, at-the-market equity distribution arrangements, underwriting agreements and common-share issuance activity that support the company's development-stage funding strategy.
Biohaven Ltd. Chief Scientific Officer Car Bruce reported equity award activity and updated holdings. On January 5, 2026, 4,750 restricted share units converted into an equal number of common shares at an exercise price of $0, reflecting a scheduled vesting from a prior grant.
To cover taxes on this vesting, 2,381 common shares were withheld by Biohaven at $9.93 per share rather than sold on the market. After these transactions, Car Bruce directly owns 7,715 common shares, which include 544 shares acquired through the company’s employee share purchase plan, and indirectly holds 30,000 common shares through an IRA. The original restricted share unit grant was 19,000 units awarded on January 5, 2025, vesting in four equal annual installments through 2028, with 9,500 units remaining outstanding after this vesting.
Biohaven Ltd. VP and Chief Accounting Officer George C. Clark reported routine equity compensation activity. On January 5, 2026, 2,500 common shares were issued upon the vesting and settlement of a restricted share unit award at an exercise price of $0, increasing his directly held common shares to 68,095 before tax withholding.
On the same date, 1,117 common shares were withheld by Biohaven at a price of $9.93 to cover tax obligations related to the vesting; the footnote clarifies that no shares were sold into the market. After these transactions, Clark directly beneficially owned 66,978 common shares and indirectly owned 20,000 common shares through an IRA, along with 5,000 restricted share units representing rights to receive additional common shares, subject to continued service and future vesting dates.
Biohaven Ltd. agreed to issue and sell 12,500,000 common shares to Janus Henderson Investors at a purchase price of $10.00 per share. The company expects to receive approximately $125 million in gross proceeds upon settlement, before fees and other expenses. These new shares are being issued as a block transaction under Biohaven’s existing “at-the-market” offering program, which is registered on Form S-3 and described in a prospectus dated October 2, 2023 and a prospectus supplement dated August 16, 2024.
Biohaven Ltd. officer reports open-market share purchase. A vice president and Chief Accounting Officer of Biohaven Ltd. (BHVN) bought 17,000 common shares on 11/17/2025 at a weighted average price of $8.5159 per share through a series of trades within a narrow price range. After this transaction, the insider beneficially owns 20,000 common shares indirectly through an IRA and 65,595 shares directly, for a combined personal stake in the company that includes 544 shares acquired under the employee share purchase plan.
Biohaven Ltd. director reports a large share purchase. A company director filed a Form 4 disclosing the acquisition of 400,000 Biohaven common shares on 11/13/2025 in an underwritten public offering at a price of $7.5 per share. Following this transaction, the director beneficially owns 2,020,071 common shares in total, held directly.
Biohaven Ltd. (BHVN) reported an insider purchase by a director who indirectly acquired 3,333,333 common shares on 11/13/2025. The transaction was coded "P" for a purchase at a price of $7.50 per share and is described as common shares acquired in an underwritten public offering.
After this transaction, indirect beneficial ownership includes 5,653,904 common shares held by the John W Childs 2013 Revocable Trust, as well as additional indirect holdings of 4,096,512, 76,570, 25,291 and 24,452 common shares through various charitable remainder trusts.
Biohaven Ltd. director and CEO Vlad Coric reported purchasing additional common shares of BHVN on 11/13/2025 in an underwritten public offering. Two trusts associated with his family each acquired 333,333 common shares at $7.50 per share, one held by The Vlad Coric Family Trust and the other by The Vladimir Coric Marital Trust.
After these transactions, reported holdings include 1,195,275 common shares held by The Vlad Coric Family Trust, 740,546 common shares held by The Vladimir Coric Marital Trust, and 109,565 common shares in a 401(k) plan. An additional 1,797,148 common shares are reported as held directly. The report notes that the family trust shares are for the benefit of family members, that his spouse is trustee, and that Coric disclaims beneficial ownership of those trust-held securities. It also states that the direct balance includes 544 shares acquired through the Biohaven Employee Share Purchase Plan on May 30, 2025.
Biohaven Ltd. received a Schedule 13G from Janus Henderson Group plc reporting beneficial ownership of 6,772,113 shares of common stock, representing 6.4% of the class as of the event date 09/30/2025. The filer reports 0 sole voting and dispositive power and 6,772,113 shared voting and dispositive power.
The filing also states that JHIUS may be deemed the beneficial owner of 6,634,902 shares, or 6.3%, with shared voting and dispositive power and no sole power. The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Biohaven Ltd. (BHVN) completed a registered public offering of 26,833,334 common shares at $7.50 per share, including the full exercise of the underwriters’ option to purchase 3,500,000 additional shares. Gross proceeds to the company were approximately $200 million before underwriting discounts, commissions, and expenses.
The offering was underwritten by J.P. Morgan and Goldman Sachs and conducted under an effective shelf registration, using a base prospectus dated October 2, 2023 and a prospectus supplement dated November 12, 2025. The underwriting agreement includes customary representations, conditions, indemnification, and termination provisions.
Biohaven Ltd. (BHVN) is offering 23,333,334 common shares at $7.50 per share in a primary offering. The deal totals $175,000,005 before fees, with underwriting discounts of $0.45 per share. The company estimates net proceeds of approximately $164.0 million and plans to use the funds for general corporate purposes.
The underwriters have a 30‑day option to buy up to 3,500,000 additional shares. Common shares outstanding are expected to be 129,136,989 immediately after the offering, or 132,636,989 if the option is fully exercised. Certain insiders, including the CEO, have indicated interest in purchasing about $60,000,000 of shares, with $5,000,000 indicated by the CEO; these indications are not binding. A 30‑day lock‑up applies to the company and to directors and officers. BHVN trades on the NYSE; the last reported sale was $8.52 on November 11, 2025.